Literature DB >> 9415357

Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia.

N Kohno1, A Yokoyama, Y Hirasawa, K Kondo, S Fujino, M Abe, K Hiwada.   

Abstract

KL-6, a MUC1 mucin preferentially expressed in regenerating type 2 pneumocytes, has been reported to be a sensitive serum marker for evaluating the disease activity of interstitial pneumonitis (IP). Type III procollagen N-terminal peptide (PIIIP) and type IV collagen 7S (7S collagen) have also been reported to be useful in the serological evaluation of the activity. Their levels were measured and their serodiagnostic values were compared simultaneously in patients with IP and alveolar pneumonia. The study population was 45 patients with IP and 12 patients with alveolar pneumonia. Serum KL-6 levels were measured by a specific enzyme immunoassay, and both serum PIIIP and 7S collagen concentrations by their correspondent radioimmunoassay kits. There were no significant difference of serum C-reactive protein level, which was evaluated as an indicator of inflammatory process, between IP and alveolar pneumonia patients. In IP, the abnormally elevated rate of KL-6 [80% (36/45)] was significantly higher than those of PIIIP [40% (18/45)] and 7S collagen [40% (18/45)]. In alveolar pneumonia, the rate of KL-6 [0% (0/12)] was significantly lower than those of PIIIP [33% (4/12)] and 7S collagen [25% (3/12)]. There were no significant correlations among serum levels of the markers. These observations indicate that the serodiagnostic value of KL-6 for IP is superior to that of PIIIP and 7S collagen, and that KL-6 has a characteristic to discriminate IP from alveolar pneumonia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415357     DOI: 10.1016/s0954-6111(97)90090-1

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

2.  KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome.

Authors:  Tomohiro Kondo; Noboru Hattori; Nobuhisa Ishikawa; Hiroshi Murai; Yoshinori Haruta; Nobuyuki Hirohashi; Koichi Tanigawa; Nobuoki Kohno
Journal:  Respir Res       Date:  2011-03-22

Review 3.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

Review 4.  Blood Biomarkers in Idiopathic Pulmonary Fibrosis.

Authors:  Julien Guiot; Catherine Moermans; Monique Henket; Jean-Louis Corhay; Renaud Louis
Journal:  Lung       Date:  2017-03-28       Impact factor: 2.584

5.  Utility of collagen-derived peptides as markers of organ injury in patients with acute heart failure.

Authors:  Kazuya Nagao; Akinori Tamura; Yukihito Sato; Reo Hata; Yuichi Kawase; Kazushige Kadota; Takahiro Horie; Naoya Sowa; Masataka Nishiga; Koh Ono; Tsukasa Inada; Masaru Tanaka
Journal:  Open Heart       Date:  2020-04-05

6.  Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond.

Authors:  Erik P Lillehoj; Irina G Luzina; Sergei P Atamas
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

7.  A comparison of KL-6 and Clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants.

Authors:  Keyi Wang; Xianmei Huang; Hui Lu; Zhiqun Zhang
Journal:  Dis Markers       Date:  2014-08-27       Impact factor: 3.434

8.  Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis.

Authors:  Ying Zhang; Qian Xin; Zhen Wu; Chaochao Wang; Yongbin Wang; Qian Wu; Rui Niu
Journal:  Med Sci Monit       Date:  2018-06-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.